| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2014 ( Subtotal = $0 ) |
| 2014 | 2013 | ALEXION PHARMA INTERNATIONAL SARL | LAUSANNE | 34 AVENUE DU TRIBUNAL-FEDERAL | | 1005 | | CHE | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 002 | 3 | FDA | 9/4/2014 | $0 |
| 2014 | 2013 | ALEXION PHARMA INTERNATIONAL SARL | LAUSANNE | 34 AVENUE DU TRIBUNAL-FEDERAL | | 1005 | | CHE | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 001 | 3 | FDA | 6/10/2014 | $0 |
| 2014 | 2013 | ALEXION PHARMA INTERNATIONAL SARL | LAUSANNE | 34 AVENUE DU TRIBUNAL-FEDERAL | | 1005 | | CHE | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 003 | 2 | FDA | 9/4/2014 | $0 |
| 2014 | 2013 | ALEXION PHARMA INTERNATIONAL SARL | LAUSANNE | 34 AVENUE DU TRIBUNAL-FEDERAL | | 1005 | | CHE | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 000 | 3 | FDA | 1/13/2014 | $0 |
| 2014 | 2011 | ALEXION PHARMA INTERNATIONAL SARL | LAUSANNE | 34 AVENUE DU TRIBUNAL-FEDERAL | | 1005 | | CHE | R01FD003745 | Phase 2 Study of ENB-0040 for the Treatment of Hypophosphatasia | 004 | 1 | FDA | 9/9/2014 | $0 |
|
|